BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31117967)

  • 1. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma.
    Wang K; Dong J; He S; Wang X; Jiang C; Hu P; Guo J; Cai X; Wang X
    BMC Cancer; 2019 May; 19(1):482. PubMed ID: 31117967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).
    Lee JY; Sun JM; Oh DR; Lim SH; Goo J; Lee SH; Kim SB; Park KU; Kim HK; Hong DS; Kim JS; Kim SG; Yi SY; Yun HJ; Hyun MS; Kim HJ; Jung SH; Park K; Ahn YC; Ahn MJ
    Radiother Oncol; 2016 Feb; 118(2):244-50. PubMed ID: 26705681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy.
    Li X; Li L; Sun R; Gao J; Li Z; Xue Y; Zhu L; Xu T; Sun C; Xi Y; Xiong W
    Eur J Med Res; 2023 Oct; 28(1):399. PubMed ID: 37794519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
    Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of weekly versus triweekly cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma: A meta-analysis.
    Chen L; Li YC; Hu M; Zhao SJ; Yang QW
    Medicine (Baltimore); 2022 Dec; 101(52):e31842. PubMed ID: 36596073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
    Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
    BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
    Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
    Li XY; Chen QY; Sun XS; Liu SL; Yan JJ; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Wen YF; Guo L; Mo HY; Chen MY; Sun Y; Ma J; Tang LQ; Mai HQ
    Eur J Cancer; 2019 Mar; 110():24-31. PubMed ID: 30739837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis.
    Tang J; Zou GR; Li XW; Su Z; Cao XL; Wang BC
    J Cancer; 2021; 12(20):6209-6215. PubMed ID: 34539894
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
    Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
    PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.